I would say the last call with NP calling out the shorts,
I would say the last call with NP calling out the shorts, he knows their intention and they were very careful not to give dates or signal anything to them. Past calls and PRs were used by many of the negative bashers as fuel for disinformation on boards. They are just making up lies about results, bringing up old news, they have no merit. Its just a bunch of noise, and stomping like children. I think CYDY knows they need to be very tactical now, and ensure they don't over communicate plans, and PRs need to be laser focused without fluff. What the last 30 days have demonstrated is that there is alot of support behind the science, long investors are holding, the SP is holding. there is no need for pointless update calls and coddling of retail investors like in the past. Drop real news when you have it, execute on actions, no pumping, no promotion stick to the script, leave the bashers as little as possible to attack.
8
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
SmartFinancial Announces Upcoming Earnings Release SmartFinancial, Inc. (NYSE: SMBK) has revealed important details regarding its Fourth Quarter earnings for the year 2024. This is an exciting time for investors and stakeholders as the company prepares to share insights into its financial performance. Earnings Release Date and Conference Call Information The earnings...
Continue Reading
IntouchCX Strengthens Trust and Safety Solutions Through Acquisition IntouchCX has recently made headlines with its acquisition of WebPurify, a leading provider of innovative content moderation solutions that harness the power of artificial intelligence. This strategic move represents a significant advancement in IntouchCX's mission to redefine Trust and Safety solutions,...
Continue Reading
Y-mAbs Therapeutics Engages Investors at Upcoming Conferences This September, Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a key player in the biopharmaceutical industry, is poised to attract investor interest. The company is known for its innovative radioimmunotherapy and antibody-based treatments designed to transform cancer care. Michael Rossi, the energetic CEO of...
Continue Reading
Overview of CorVel's Financial Performance CorVel Corporation (NASDAQ: CRVL) recently unveiled impressive results for the quarter and fiscal year, showcasing strong revenue gains and enhanced earnings metrics. The quarterly revenue hit $232 million, a notable rise from $207 million compared to the same quarter last year. This upward trend is mirrored across the fiscal...
Continue Reading
IQAX eBL Interoperability Approval Highlights IQAX Limited has made significant strides in enhancing its electronic bill of lading (eBL) solution by receiving official approval from the International Group of P&I Clubs (IG P&I Clubs). This approval affirms the capabilities of IQAX eBL's interoperable addendum, empowering users to perform eBL transactions across different...
Continue Reading
